FUNDING & OPPORTUNITIES
The Milner Therapeutics Institute is part of the School of Biological Sciences and the School of Clinical Medicine at the University of Cambridge, and is dedicated to the conversion of ground breaking science into therapies. Based on the Cambridge Biomedical Campus, the institute is surrounded by a global therapeutic alliance of 74 SMEs, pharma companies, academic institutions and venture capital firms.
We periodically run calls that offer physical space for startup companies, as well as opportunities for funding and collaboration. Please see below for a list of our current opportunities.
The Milner Therapeutics Consortium is seeking proposals for academic-industry research collaborations that can transform pioneering science into therapies by developing better models of disease and uncovering novel and biologically informed targets.
Do you have an idea for a potential pre-clinical collaborative project that would benefit from industry expertise and know-how? Our pharma partners in the Milner Therapeutics Consortium are working together with academics at the University, Babraham and Wellcome Sanger Institutes on early stage research collaborations to apply novel technologies and advanced disease models to better understand disease mechanisms, and to discover and validate new therapeutic targets.
For more details click here.
Onco-Innovation Rapid Response Data Analysis Call
The Onco-Innovation Programme at the Milner Therapeutics Institute is seeking proposals from CRUK Cambridge Centre members for data analysis projects that could benefit from our multimodal data-driven AI/machine learning approaches.
Do you have clinical or experimental “multi-omic” data sets that would benefit from expert data integration and unsupervised network-based machine learning analysis? Our computational research team, led by Dr Namshik Han, use bespoke AI and machine learning methods to identify new signatures of disease and therapeutic targets as well as network analysis to gain a deep understanding of the underlying causes of disease. Integration of data sets to provide systematic multi-omics analysis, with biological insight is the key focus in order to answer clinically relevant, scientific questions.
We are seeking applications for new collaborative projects from researchers and clinicians with multiple data sets, who wish to address questions of clinical importance through the integration and interrogation of these data sets.
Our Rapid Response Data Analysis Call will launch on Monday 12th April 2021 and will be open for 4 weeks. Further information and application details will be available here.
Are you a start-up interested in bio-incubator space?
We currently have a unique opportunity for you to be part of a vibrant Institute in a much sought after location on Cambridge Biomedical Campus. The Milner Therapeutics Institute has limited space for research intensive, R&D companies, working in an areas related to the Institute’s expertise (e.g. functional genomics, early target discovery, therapeutics). You will be working side by side with academics, entrepreneurs and industry scientists.
Pfizer CTI Call 2021
Milner Consortium company Pfizer has a current call open for research proposals to their Centres for Therapeutic Innovation. Please initially contact the Milner team on firstname.lastname@example.org if you are considering an application.
The 2021 CTI Call for Proposals is seeking partnering opportunities for novel targets in the areas described below with applications across Pfizer’s core therapeutic areas.
Submission Deadline: June 28th 2021
CTI pursues breakthrough science at the earliest stages. We offer industry-leading drug development expertise combined with the infrastructure of a large biopharmaceutical company in an open, collaborative environment. Once we identify promising research, we work with academic investigators to navigate the challenges inherent in early translational science through hands-on support from subject matter experts across Pfizer and through our network in the broader life science community. Our most successful, enduring relationships rely on close collaboration between scientists. CTI assigns a scientific champion for each investigator and project, who understands and manages the project needs, and coordinates access to Pfizer’s global capabilities and scale to deliver optimal outcomes.
Disease areas of interest include:
Inflammation and Immunology | Internal Medicine | Oncology | Rare disease
A full list of mechanisms and approaches within these areas is available on the CTI website, including areas of emerging science that are a priority across several areas:
Cellular Senescence | Repeat Expansion diseases | DNA Damage Response
Cambridge Academy of Therapeutic Sciences (CATS) Funding Call
The Wellcome Trust has awarded Cambridge University an Institutional Translational Partnership Award (iTPA).
The Developing Concept Fund is intended to pump-prime the translation of novel therapeutics, devices and diagnostics, including repurposing of existing therapies towards a clinical end.
It is intended that successful project applicants will obtain evidence of the feasibility (or otherwise) of their translational plans, strengthening their chances of obtaining downstream funding. The focus will be on very early stage translational research and projects should be seen as a way to gain sufficient evidence to support follow on funding such as MRC CiC applications. Projects will be encouraged to include a substantive cross-disciplinary collaborative component between basic scientists, clinical scientists and/or industry (as appropraite for the project). Proposals must be led by a Principal Investigator at the University of Cambridge.
The fund supports projects up to a maximum of £50,000 each for 9 months.
The call is now open. Deadline for applications is 1st June 2021.
For more details, please visit https://www.ats.cam.ac.uk/funding/wt-developing-concept-fund